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a  b  s  t  r  a  c  t
Melastoma  malabathricum  L., Melastomaceae,  has  been  traditionally  used  to relieve  diverse  pain-related
ailments.  The  objectives  of the  present  study  were  to  determine  the  antinociceptive  activity  of  methanol
extract  of  M.  malabathricum  leaves  and  to  elucidate  the  possible  mechanisms  of  antinociception  involved
using  various  rats’  models.  The  extract  (100,  250,  and  500  mg/kg)  was  administered  orally  60 min  prior
to subjection  to  the respective  test. The  in vivo  acetic  acid-induced  abdominal  constriction,  formalin-
induced  paw  licking,  and hot  plate  tests  were  used  as the models  of nociception  to  evaluate  the extract
antinociceptive  activity.  Further  studies  were  carried  out to determine  the  role  of opioid  and  vanil-
loid  receptors,  glutamate  system  and  nitric  oxide/cyclic  guanosine  phosphate  (NO/cGMP)  pathway  in
modulating  the  extract  antinociceptive  activity.  From  the  results  obtained,  M.  malabathricum  exhibited
signiﬁcant  (p <  0.05)  antinociceptive  activity  in  all  the  chemical-  and  thermal-induced  nociception  mod-
els.  Naloxone  (5  mg/kg),  a non-selective  opioid  antagonist,  failed  to  signiﬁcantly  affect  the  antinociceptive
activity  of MEMM  when  assessed  using  the abdominal  constriction-,  hot  plate-  and  formalin-induced  paw
licking-test.  M.  malabathricum  also  signiﬁcantly  (p < 0.05)  reversed  the  nociceptive  response  in capsaicin-
and glutamate-induced  paw  licking  test.  Furthermore,  only  l-arginine  (a nitric  oxide  precursor)  alone,  but
not,  NG-nitro-l-arginine  methyl  esters  (l-NAME;  an  inhibitor  of NO  synthase),  methylene  blue  (MB;  an
inhibitor  of  cGMP),  or  their  combination  thereof,  signiﬁcantly  (p  < 0.05)  block  the  antinociceptive  activity
of M.  malabathricum. In conclusion,  M.  malabathricum  exerted  a non-opioid  antinociceptive  activity  at
the central  and  peripheral  levels  partly  via the inhibition  of vanilloid  receptors  and glutamatergic  system,
and  activation  of the  NO-mediated/cGMP-independent  pathway.
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Some of the most common ailments that affected millions of
eople worldwide are pain and inﬂammation (Raghav et al., 2006;
ang et al., 2011). Therefore, researches in the ﬁelds of pain and
nﬂammation, particularly on ﬁnding appropriate drugs to treat
hem, have tremendously increased these past few years. This
laim is suggested based on the rapid developments in the ﬁeld
f synthetic and medicinal chemistry that saw increase in reports
n newly synthesize drugs including those for the treatment of
ain and inﬂammation. However, many of synthetic drugs are
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reativecommons.org/licenses/by-nc-nd/4.0/).eira  de  Farmacognosia.  Published  by  Elsevier  Editora  Ltda.  This  is an  open
 BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
withdrawn lately after their introduction into the market because
of the adverse side effects associated with their prolong used.
For example, chronic used of morphine, a currently prescribed
analgesic drug, has been associated with the development of
tolerance and dependence. Therefore, alternative agents with less
or, possibly, no unwanted side effects are required and plant-based
natural products are and have been the important sources of
those alternative agents (Verpoorte, 1998). Natural products from
plants have long been recognized as the important sources of
therapeutically effective medicines (Cragg et al., 2003).
Melastoma malabathricum L. (family Melastomaceae) is a ﬂow-
ering plant native to the Southeast Asian region including Malaysia.
It is the sole species in the genus Melastoma and has been classiﬁed
as a weed, and can be found to grow extensively in the waste-
land areas. Commonly called the “Straits Rhododendron” and locally
ora Ltda. This is an open access article under the CC BY-NC-ND license (http://
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nown to the Malay as “Senduduk”, M.  malabathricum has been
idely used in the Malay as well as others traditional medicines
Rajenderan, 2010). According to several reports, the leaves, in
articular, have been applied either pounded, grounded or as
ecoction, by several tribes and population to treat ailments such
s stomach ulcers, dysentery and diarrhoea, those associated with
ain (i.e., toothache and stomachache), to accelerate wound heal-
ng, for post-natal care and prevention of scars from small pox
nfection, and, postpartum remedy (Grosvenor et al., 1995; Ong
nd Nordiana, 1990; Sharma et al., 2001; Sulaiman et al., 2004;
oosita et al., 2008). Scientiﬁcally, the leaves of M.  malabathricum
ave been reported to exert no acute toxicity and (Sunilson et al.,
009), antibacterial (Grosvenor et al., 1995; Wiart et al., 2004),
ntiviral (Grosvenor et al., 1995), antioxidant (Nazlina et al., 2008),
ytotoxic (Nazlina et al., 2008), anticoagulant (Manicam et al.,
010), antiulcer (Hussain et al., 2008), antidiarrheal (Sunilson et al.,
009), anti-inﬂammatory (Susanti et al., 2008; Zakaria et al., 2008),
ntinociceptive (Sulaiman et al., 2004; Zakaria et al., 2008) and
ntipyretic (Zakaria et al., 2008) activities. Phytochemical screening
f the M.  malabathricum leaves demonstrated the presence of
avonoids, triterpenes, tannins, saponins, steroids (Zakaria et al.,
008; Simanjuntak, 2008; Faravani, 2009), alkaloids (Zakaria et al.,
008), glycosides and phenolics (Simanjuntak, 2008; Faravani,
009). However, the phytochemical analysis of methanol extract
f M.  malabathricum leaves (MEMM)  revealed only the presence of
avonoids, glycosides, phenolics, triterpenes, tannins, saponins and
teroids but no alkaloids. The previous antinociceptive activity of M.
alabathricum leaves, in particular, has been investigated using the
queous and ethanol extract of the leaves with attempt only made
o determine the role of opioid receptors reported. In the present
tudy, the methanol extract of M.  malabathricum leaves (MEMM)
as used to further study the antinociceptive activity of M. mala-
athricum and the mechanisms of action involved. The mechanisms
f action to be studied include the role of opioid and vanilloid recep-
ors, glutamate system and nitric oxide/cyclic guanosine phosphate
NO/cGMP) pathway.
aterials and methodology
lant collection and preparation of MEMM
The leaves of Melastoma malabathricum L. was collected
etween June and July 2012 around the Universiti Putra Malaysia
UPM), Malaysia and certiﬁed by a botanist, Dr. Shamsul
hamis, from the Institute of Bioscience (IBS), Universiti Putra
alaysia (UPM), Serdang, Selangor, Malaysia. A voucher specimen
ACP0017) has been earlier deposited at the Herbarium of the Lab-
ratory of Natural Products, IBS, UPM, Malaysia. The procedure for
reparation of MEMM  was carried out as described in detail by
akaria et al. (2008).
rugs and chemicals
The following reagents and drugs were used: methanol (Fischer
cientiﬁc, UK), DMSO, formalin, acetic acid, morphine, acetyl-
alicylic acid (ASA), naloxone, capsaicin, glutamate, l-arginine,
G-nitro-l-arginine methyl esters (l-NAME) and methylene blue
MB) (Sigma, USA). The drugs were prepared by dissolving them in
istilled water. The MEMM  was dissolved in vehicle (10% DMSO)
mmediately before used. All solutions were administered in the
olume of 10 ml/kg.nimals
Male Sprague Dawley (SD) rats (180–200 g; 8–10 weeks old) and
ale ICR mice (25–30 g; 5–7 weeks old), purchased from Che Nurmacognosia 26 (2016) 586–594 587
Supplier, Selangor, Malaysia, were transferred to the Animal Hold-
ing Unit, International Islamic University Malaysia (IIUM), Pahang,
Malaysia and allowed to acclimatize for one week prior to the
experimentation. The animals were cared and handled according
to the procedures described in detail by Mohd. Sani et al. (2012).
The study protocol of the present study was approved by the Ani-
mal  Ethics Committee of International Islamic University Malaysia
[IIUM / IACUC Approval / 2016/ (9) (58)] and were performed in
accordance with the Integrated Centre for Research of Animal Care
and Use (ICRACU) guidelines.
Acute toxicity study of MEMM
Acute toxicity studies were carried out according to the “Guide-
line for Testing of Chemicals – Acute Oral Toxicity – Fixed
Dose Procedure (OECD No. 423)” (OECD, 2002). Rats were fasted
overnight prior to the administration of test solutions. The treated
group obtained a single dose of 5000 mg/kg MEMM  while one group
each obtained either vehicle or distilled water (10 ml/kg) by gavage.
Then, the animals were monitored separately at least once during
the ﬁrst 30 min  after dosing, occasionally during the ﬁrst 24 h and
daily thereafter for 14 days. Food and water were provided ad libi-
tum. The mortality, body weight and behavioural screening were
recorded daily for 14 days after treatment. The rats that survived
were euthanized and macroscopic analysis and the weight of vital
organs were recorded. These organs were ﬁxed in 10% formalin for
histological assessment.
Antinociceptive activity
Acetic acid-induced abdominal constriction test
The acetic-acid-induced abdominal constriction test was car-
ried out according to the method described in detail by Collier et al.
(1968) but with slight modiﬁcations. The mice (n = 6) were pre-
treated orally (p.o.) with 10% DMSO (negative control), 100 mg/kg
ASA (positive control), or MEMM  (100, 250, and 500 mg/kg) prior
to assessment using the abdominal constriction test. Sixty minutes
after the respective test solution administration, the mice were
injected via intraperitoneal (i.p.) route with phlogistic agent (0.6%
acetic acid). The animals were immediately placed individually into
glass cage and 5 min  were allowed to elapse. The abdominal con-
striction resulting from the injection of acetic acid consists of a
contraction of the abdominal together with a stretching of at least
one hind limb. The number of abdominal constrictions produced in
these animals was counted cumulatively for 25 min. Antinocicep-
tive activity, indicated by the reduction in the mean of the number
of abdominal constrictions in the test groups compared to the con-
trol group, was  calculated as the percentage inhibition of abdominal
constrictions (percentage of inhibitory level) using the following
formula: [mean of (control − test group)/control group × 100%].
Hot plate test
The hot plate test was  carried out according to the method
described by Hunskaar et al. (1986) but with slight modiﬁcations.
The mice (n = 6) were pre-treated (p.o.) with 10% DMSO (nega-
tive control), 5 mg/kg morphine (positive control), or MEMM  (100,
250, and 500 mg/kg) prior to assessment using the hot plate test.
The temperature of the metal surface (Ugo Basile 7280) was set at
50 ± 0.2 ◦C. Sixty minutes after the respective test solution admin-
istration, the mice were placed on the heated metal surface and
the latency to a discomfort reaction (licking paws or jumping) was
recorded. The cut-off time of 20 s was  chosen to avoid tissue injury.
Latency was  record before and 60, 90, 120, 150, 180, 210 min  fol-
lowing the oral administration of treatments. The prolongation of
latency times compared with the values of the controls was  used
for statistical comparison.
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ormalin-induced paw licking test
The formalin induced paw licking test (also known as forma-
in test) was carried out as described by Hunskaar and Hole (1987)
ut with slight modiﬁcations. Rats (n = 6) were administered p.o.
ith 10% DMSO (negative control), 5 mg/kg morphine or 100 mg/kg
SA (both act as the positive controls), or MEMM (100, 250, and
00 mg/kg) prior to assessment using the formalin test. Pain was
nduced by injecting 50 l of 5% formalin in the sub-plantar region
f the right hind paw 60 min  after the test solutions administra-
ion. Immediately after the phlogistic agent administration, the rats
ere individually placed in a transparent glass cage observation
hamber. The amount of time that the animal spent licking the
njected paw, considered as an indicator of pain, was recorded for
he duration of 30 min  in two phases, known as the early (0–5 min)
nd late (15–30 min) phases.
echanisms of antinociceptive activity of MEMM
apsaicin-induced paw licking test
The capsaicin-induced paw licking test was used to investigate
he role of vanilloid receptors in the modulation of MEMM  antinoci-
eptive action and the procedure adopted has been described in
etail by Sakurada et al. (1992) but with slight modiﬁcations. Rats
ere pre-treated orally with 10% DMSO or MEMM  (100, 250, and
00 mg/kg) 60 min  prior to assessment using the respective test.
ixty min  after the administration of test solutions capsaicin was
njected (1.6 g/paw, 20 l) into the intraplantar (i.pl.) region of the
at’s right hind paw. Immediately after the phlogistic agent admin-
stration, the rats were individually placed in a transparent glass
age observation chamber and observed individually for 5 min  after
he capsaicin injection. The amount of time the animals spent lick-
ng the injected paw was recorded with a chronometer and was
onsidered as an indication of nociception.
lutamate-induced paw licking test
The glutamate-induced paw licking test was used to inves-
igate the role of glutamatergic system in the modulation of
EMM  antinociceptive action and the procedure adopted has been
escribed by Luiz et al. (2007) with slight modiﬁcations. Rats
ere pre-treated orally with 10% DMSO or MEMM  (100, 250, and
00 mg/kg) 60 min  prior to assessment using the respective test.
 volume of 20 l of glutamate (10 mol/paw, in normal saline)
as injected via i.pl.  route in the right hind paw of rats 60 min
ollowing the test solutions administration. Immediately after the
hlogistic agent administration, the rats were individually placed
n a transparent glass cage observation chamber and observed indi-
idually from 0 to 15 min  after the glutamate injection. The amount
f time the animals spent licking or biting the injected paw was
ecorded with a chronometer and was considered as an indication
f nociception.
nvolvement of opioid receptor
To determine the role of opioid receptors in the modulation of
EMM  antinociceptive activity, six groups of animals (n = 6) were
re-treated (i.p.) with a non-selective opioid antagonist, naloxone
5 mg/kg; i.p.) for 15 min  followed by the oral administration of
he most effective MEMM  dose (500 mg/kg) or 10% DMSO. Sixty
inutes later, the animals were assessed using the acetic acid-
nduced abdominal constriction test, hot plate test or formalin test,
espectively (Mohd. Sani et al., 2012).
nvolvement of nitric oxide/cyclic-guanosine monophosphate
NO/cGMP) pathway
To determine the role of nitric oxide/cyclic-guanosine
onophosphate (NO/cGMP) pathway in the modulation of
EMM  antinociceptive activity, the method described in detailmacognosia 26 (2016) 586–594
by Mohd. Sani et al. (2012) was adopted with slight modiﬁ-
cations. In this study, the mice (n = 6) were pre-treated with
20 mg/kg l-arginine, l-NAME, MB,  or their respective combination
(l-arginine with l-NAME or l-arginine with MB)  followed 5 min
later by pre-treatment with 10% DMSO or MEMM  (500 mg/kg),
respectively. Sixty minutes later, the animals were assessed using
the abdominal constriction test.
HPLC and GCMS analysis of MEMM
The HPLC analysis of MEMM  has been carried out previously
and the detailed method was  published by Kamisan et al. (2014).
From the analysis, ﬂavonoids were generally detected based on
the UV–vis spectra wavelength while quercitrin was speciﬁcally
detected based on the comparison of chromatogram obtained for
MEMM  against those of several pure ﬂavonoids. In addition to the
HPLC ﬁnding, GCMS analysis was  also performed on MEMM.
GC–MS analysis of MEMM  was performed using Agilent 7890A
(Agilent Technologies) coupled with MSD  quadrupole detector
5975C (Agilent Technologies). Separation of analytes by gas chro-
matography was carried out using the Hewlett Packard HP-5MS
silica capillary column (30 m × 0.25 mm × 0.25 mm).  For GC–MS
detection, an electron ionization system with ionizing energy of
70 eV was used. Helium gas (99.999%) was  used as the carrier gas
at constant ﬂow rate 1 ml/min and an injection volume of 1 l
was employed (split ratio of 1:10); injector temperature 250 ◦C;
ion-source temperature 280 ◦C. The oven temperature was pro-
grammed from 100 ◦C (isothermal for 2 min), with an increase of
10 ◦C/min to 200 ◦C, then 12 ◦C/min to 280 ◦C, ending with a 17 min
isothermal at 280 ◦C. Mass spectra were taken at 70 eV; a scan inter-
val of 0.5 s and fragments from 45 to 450 Da. Total GC running
time was  35.50 min. The relative % amount of each component was
calculated by comparing its average peak area to the total areas.
The software adopted to handle mass spectra and chromatograms
was a Turbomass. For the identiﬁcation of compounds, interpreta-
tion on mass spectrum GC–MS was  conducted using the database
of National Institute Standard and technology (NIST) having more
than 62,000 patterns. The spectrum of the unknown component
was compared with the spectrum of the known components stored
in the NIST library.
Results
Acute toxicity effect of MEMM
All animals in the treatment and control groups demonstrated
an increase in body weight at weeks 1 and 2 in comparison to day
0. Neither alteration in the behavioural pattern nor mortality was
observed throughout the duration of experimentation. In addition,
no changes in food and water intake, and behaviour were detected
among the animals. The vital organs showed no signiﬁcant changes
in their respective relative weight while the respective microscopic
analysis demonstrated no signs of toxicity (data not shown). More-
over, the single oral administration of 5000 mg/kg MEMM  did not
generate any sign of toxicity in the treated animals after 14 days.
Based on these observations, the extract was suggested to possess
an LD50 that is greater than 2000 mg/kg body weight.
Acetic acid-induced abdominal constriction test
The MEMM,  at all tested doses, demonstrated a signiﬁcant
(p < 0.001) and dose-dependent antinociceptive activity when
assessed using the abdominal constriction test (Fig. 1) with the per-
centage of analgesia ranging between 33 and 62%. The 250 mg/kg
MEMM  produced an antinociceptive activity that was of equal
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Fig. 1. Antinociceptive activity of MEMM  assessed by the acetic acid-induced
abdominal constriction test in mice. Acetic acid administrated by intraperitoneally
60  min  before pre-treated with DMSO as vehicle (control), acetylsalicylic acid (ASA),
or  MEMM (100, 250 and 500 mg/kg). All treatments administrated via oral route.
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Fig. 2. Antinociceptive activity of MEMM  assessed using the formalin-induced paw
licking test. (A) Effect of MEMM  recorded at the early phase (0–5 min), and; (B)
effect of MEMM  recorded at the late phase (15–30 min). Each column represents the
mean ± SEM of 6 rats. The rats were pre-treated with vehicle (10% DMSO) as control,
MEMM  (100, 250, and 500 mg/kg, p.o.), acetylsalicylic acid (ASA, p.o.), or morphine
(5  mg/kg, p.o.), 60 min before i.pl. injection of formalin. The asterisks denote the
T
A**Data differed signiﬁcantly (p < 0.001) when compared to 10% DMSO-treated
roup. #Data was  not signiﬁcant when compared together.
ffectiveness when compared to the positive control (100 mg/kg
SA).
ot plate test
Table 1 shows the antinociceptive proﬁle of orally-administered
EMM  as assessed using the hot plate test. The MEMM,  at the dose
f 250 mg/kg, exhibited signiﬁcant (p < 0.001) activity at the inter-
al time of 60, 90 and 120 min  while the 500 mg/kg MEMM exerted
igniﬁcant (p < 0.001) antinociception until the end of experiment.
o-administration with naloxone (5 mg/kg; i.p.) failed to inhibit
he 500 mg/kg MEMM  antinociceptive activity. Overall, the 5 mg/kg
orphine demonstrated the most effective effect when compared
o the MEMM  at all doses used.
ormalin-induced paw licking test
MEMM  demonstrated a signiﬁcant (p < 0.001) antinociceptive
ctivity in a dose-dependent manner in both phases of the formalin-
nduced paw licking test as shown in Fig. 2A and B, respectively.
n comparison to MEMM,  5 mg/kg morphine also attenuated both
hases while 100 mg/kg ASA only reduced the nociception in the
ate phase. Overall, morphine was effective than the ASA and
EMM  in both phases of the formalin test.
apsaicin-induced paw licking testThe antinociceptive proﬁle of MEMM  assessed using capsaicin-
nduced paw licking test is shown in Fig. 3. All doses of
EMM  demonstrated a signiﬁcant (p < 0.05) and dose-dependent
able 1
ntinocicpetive activity of MEMM  assessed by the hot plate test in mice.
Treatment Dose (mg/kg) Latency o
0 min  60 min  90 min  
10% DMSO – 6.97 ± 0.22 6.97 ± 022 6.90 ± 
Morphine 5 5.77 ± 0.15 17.37 ± 1.03a 18.25 ± 
MEMM
100 6.84 ± 0.33 10.19 ± 0.91a 10.56 ± 
250 6.84 ± 0.23 12.38 ± 1.00a 11.34 ± 
500 6.75 ± 0.30 12.51 ± 1.38a 14.1 ± 
Naloxone 5 6.38 ± 0.27 6.43 ± 0.41 5.98 ± 
Naloxone + MEMM 5 + 500 6.97 ± 0.16 13.55 ± 2.06a 14.15 ± 
a Data differed signiﬁcantly (p < 0.05) when compared against the control (10% DMSO-tsigniﬁcance levels as compared to control, ***p < 0.001 by one-way ANOVA followed
by Dunnett’s post hoc test. ***Data differed signiﬁcantly (p < 0.05) when compared
to  the 10% DMSO-treated group.
antinociception against capsaicin-induced nociception with the
percentage of analgesia ranging between 29% and 64%.
Glutamate-induced paw licking test
Fig. 4 shows the antinociceptive proﬁle of MEMM  assessed using
the glutamate-induced paw licking test. All doses of MEMM  also
exerted a signiﬁcant (p < 0.05) and dose-dependent antinociep-
tion against glutamate-induced nociception with the percentage
of analgesia ranging from 17% to 72%.Involvement of opioid receptors
The effects of non-selective opioid antagonist (naloxone,
5 mg/kg) on MEMM  antinociceptive activity was evaluated using
f discomfort(s) at respective time interval (min)
120 min 150 min  180 min  210 min
0.23 6.15 ± 0.15 6.92 ± 0.23 6.88 ± 0.29 6.35 ± 0.17
0.74a 16.52 ± 1.22a 13.67 ± 1.43a 11.22 ± 1.11a 10.48 ± 0.58a
1.68a 6.70 ± 0.32 6.73 ± 0.37 7.77 ± 0.33 7.38 ± 0.46
0.89a 11.80 ± 1.37a 9.10 ± 0.61a 9.39 ± 1.00a 8.74 ± 0.37a
0.67a 15.12 ± 1.00a 13.14 ± 1.10a 10.28 ± 0.20a 9.70 ± 0.130a
0.46 6.1 ± 0.21 5.93 ± 0.68 6.13 ± 0.58 5.67 ± 0.54
1.86a 12.68 ± 1.63a 11.90 ± 0.36a 10.62 ± 0.36a 9.83 ± 0.31a
reated) group.
590 E.S. Jaios et al. / Revista Brasileira de Far
50
40
30
20
10
0
Control
(10% DMSO)
Li
ck
in
g 
tim
e 
(s)
100
(29.3)
∗∗∗ (41.7)
∗∗∗
(63.9)
∗∗∗
250
MEMM (mg/kg)
500
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the abdominal constriction test, hot plate test, and formalin test and
are shown in Fig. 1, Table 1, and Fig. 2A and B, respectively. Naloxone
did not signiﬁcantly (p < 0.05) reversed the antinociceptive activity
of 500 mg/kg MEMM  when assessed using the abdominal constric-
tion test, hot plate test and formalin test.
Involvement of NO/cGMP pathway
Fig. 5A shows the effect of l-arginine, l-NAME, or their com-
bination on antinociceptive activity of 500 mg/kg MEMM  assessed
using the abdominal constriction test. Pre-treatment of rats with
l-arginine alone did not affect the acetic acid-induced nocicep-
tion but signiﬁcantly (p < 0.05) reversed the antinociception of
500 mg/kg MEMM.  On the other hand, pre-treatment of rats with
l-NAME alone exerted signiﬁcant (p < 0.05) antinociceptive activity
but failed to enhance the extract’s antinociceptive activity. More-
over, pretreatment with both l-arginine and l-NAME also failed to
signiﬁcantly changed the extract’s antinocicpetion. Therefore, only
the presence of NO donor (l-arginine) signiﬁcantly affects MEMM
antinociceptive activity.
Fig. 5B shows the effect of l-arginine, MB  or their combination
on antinociceptive activity of 500 mg/kg MEMM  assessed using the
abdominal constriction test. Pre-treatment of rats with MB alone
produce a signiﬁcant (p < 0.05) antinociceptive effect, which is not
affected by early pre-treatment with l-arginine. Moreover, MB
alone or in combination with l-arginine did not help to increase the
antinociceptive activity of MEMM.  Thus, inhibitor of cGMP pathway
did not affect the extract’s antinociception.
GCMS analysis of MEMM
A total of 30 peaks were identiﬁed from MEMM  with
the major compounds constituted of 9-octadecenamide (48%),
3-methyl quinoline (7.8%), propanoic acid (5.8%), methyl--
d-galactopyranoside (6.8%), methyl--d-glucopyranoside (3.9%),
hexadecanoic acid, methyl ester (3.4%), hexadecanoic acid (2.9%),
hexadecanamide (2.9%), furfural (2.3%), pyrogallol (2.3%), myris-
tamide (1.8%), 9,12,15-octadecatrienoic acid, methyl ester (2.1%),
2-methyl-l-mannomethylpyranoside (1.7%), -conicein (1.6%),
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odecanedioic acid, dimethyl ester (1.6%) and 9-octadecenoic acid
1.3%).
iscussion
The management of pain using currently available analgesics
ave been over shadowed by various adverse effects. Morphine,
hich has been the drug of choice for the treatment of pain, has
een known to cause dependence and tolerance upon its prolong
sed (Rang et al., 2011). In an attempt to contribute towards ﬁnd-
ng new analgesic drug with low or, possibly, no adverse effects,
he present study was conducted to determine the antinociceptive
otential of MEMM  using various chemical- and thermal-induced
odels of nociception in laboratory animals. Although there have
een three reports on the antinociceptive activity of M. mala-
athricum leaves, the three papers reported the use of ethanol,
queous and chloroform extracts as their source of antinocicep-
ive study and that those extracts were administered systemically,
hich are either by the intraperitoneal or subcutaneous routes
Sulaiman et al., 2004; Zakaria et al., 2006; 2008). In contrast to
hose reports, the present study used methanol extract that was
dministered orally into the rats. Although the use of ethanol
xtract almost resembles the current used of methanol extract, the
ormer administration via the intraperitoneal route did not repre-
ent the traditional way of consuming the extract. Moreover, the
queous and chloroform extracts of M.  malabathricum have been
roven to exert antinociceptive activity and, therefore, justify the
se of intermediate solvent like methanol to extract out both the
ntinociceptive-bearing polar ad non-polar bioactive compounds
rom M.  malabathricum.
In the present study, MEMM  was found to exert antinocicep-
ive activity at both the peripheral and central levels with the
on-opioid-mediated activity seen at both levels. The non-opioid
echanism is suggested based on our ﬁndings that naloxone failed
o inhibit the extract’s activity when assessed using all nocicep-
ive assays. Interestingly, the antinociceptive activity of MEMM  is
lso suggested to involve inhibition of the vanilloid receptors and
lutamatergic system as MEMM  attenuated both the capsaicin-
nd glutamate-induced models of nociception. Moreover, MEMM  is
lso suggested to exert antinociceptive activity via the mechanisms
f action that did not involve activation of the NO/cGMP pathway as
re-challenging the extract with l-NAME or MB  also failed to inhibit
EMM  antinociceptive activity. The ﬁnding that only l-arginine,
ur not l-NAME or MB,  signiﬁcantly reversed the antinociceptive
ctivity of MEMM  suggested that the presence of NO affected the
xtract via a pathway that was independent of cGMP action (Cui
t al., 2005).
Several other mechanisms of action could be proposed based
n the results obtained. Pain sensation can be produced by various
ypes of stimuli (i.e., mechanical, thermal and chemical), hence the
xistence of mechanosensitive, thermosensitive and chemosensi-
ive pain receptors are suggested (Tandon et al., 2003). The extract
bility to inhibit at least two of the stimuli, which is represented
y the respective acetic acid-induced abdominal constriction and
ormalin-induced paw licking tests, and the hot-plate test, is an
ndicative of its ability to inhibit the peripheral and central nocicep-
ive mechanisms. Moreover, MEMM  also attenuated both phases of
he formalin test and, taking these things together, it is plausible
o suggest that MEMM  possesses the characteristic of centrally act-
ng analgesics. However, since MEMM  did not work on the opioid
eceptors at the peripheral and central levels, it might be a right
andidate for the development of analgesic to replace morphine.Several mechanisms of antinociception could also be suggested
ased on the nociceptive models applied in the present study.
he acetic acid-induced abdominal constriction test is a typi-
al model for assessment of peripheral antinociceptive activitymacognosia 26 (2016) 586–594 591
of new or potential analgesic agents. Other than being a sensi-
tive model (Collier et al., 1968; Bentley et al., 1981; Mohd. Sani
et al., 2012), this assay represents the stimulation of peripheral
nociceptive mechanism via the acetic acid-induced release of sev-
eral pro-inﬂammatory or nociceptive-endogenous mediators (i.e.,
bradykinin, serotonin, histamine, substance P or prostaglandins
(PGE2 and PGF2)) (Deraedt et al., 1980; Ribeiro et al., 2000;
Tandon et al., 2003), which caused subsequent activation of periph-
eral nociceptive neurons within the peritoneal cavity. In addition,
the nociceptive response induced by acetic acid depends on the
production of nitric oxide (NO) (Larson et al., 2000). Moreover,
the acetic acid-induced nociception observed using the abdom-
inal constriction test was  attenuated by both the peripherally-
and centrally-mediated analgesics. Therefore, our present results
imply that MEMM  may  exerted in part a peripherally-mediated
antinociceptive activity, which may  to a certain extent resulted
from the inhibition of the synthesis or action of some of the pro-
inﬂammatory mediators mentioned above. In addition, the extract
might also cause decrease in the production of NO and/or cytokines,
thereby interfering with the mechanisms of signal transduction in
the primary afferent nociceptors.
Nevertheless, the abdominal constriction test is not a speciﬁc
test as certain type of non-analgesics like muscle relaxants can also
give false positive results, which could lead to misinterpretation of
the results (Le Bars et al., 2001; Mohd. Sani et al., 2012). Therefore,
additional assessment of MEMM’s  antinociceptive potential using
other models of nociception need to be conducted. To conﬁrm the
possible mechanisms of antinociception involved, the MEMM was
further subjected to the hot-plate and formalin-induced paw lick-
ing tests. These tests are considered as the more speciﬁc tests for
determining the involvement of the central and/or peripheral levels
of antinociception (Mohd. Sani et al., 2012).
The hot plate test, which measured thermal-induced noci-
cpetion at the supra-spinal and spinal levels, is a nociceptive model
suitable for assessing the potential of any compounds/extracts to
exert antinociceptive activity at central level. It has the advan-
tage of being selective and sensitive only to the centrally-, but not
peripherally-acting analgesics (Hosseinzadeh and Younesi, 2002;
Giglio et al., 2006). The ability of MEMM  to prolong the latency
to feeling discomfort indicates the extract potential to inhibit
the thermal-induced nociception and, therefore, suggested the
involvement of centrally-mediated antinociception. Taking into
account the ability of MEMM  to attenuate nociceptive stimuli when
assessed using the abdominal constriction and hot plate tests, it
is plausible to suggest that MEMM  exerts peripheral and central
antinociceptive activity and, hence, demonstrated the characteris-
tic of strong analgesics.
The ability of MEMM  to exhibit antinociceptive activity at
the peripheral and central levels was further conﬁrmed by ﬁnd-
ings made using the formalin-induced paw licking test (Tjolsen
et al., 1992; Mohd. Sani et al., 2012). Other than that, this
model of nociception can also provide information on the effect
of compounds/extracts towards the inﬂammatory- and non-
inﬂammatory-mediated pain (Hunskaar and Hole, 1987; Mohd.
Sani et al., 2012). These advantages of using formalin test could
be attributed to its characteristic distinct biphasic nociceptive
response resulting from the intraplantar injection of phlogistic
agent (formalin) (Hunskaar and Hole, 1987; Tjolsen et al., 1992).
The two  distinct phases known as the ﬁrst/early phase and the
second/late phase occur between 0–5 min  and 15–30 min  follow-
ing the phlogistic agent administration, respectively (Shibata et al.,
1989). The early phase corresponds to the neurogenic and non-
inﬂammatory-mediated nociceptive response, and represents the
centrally-acting nociception. This neurogenic pain is described as
an intensely painful process resulting from direct formalin acti-
vation of transient receptor potential A1 (TRPA1) cation channels
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ocated at the sensory C-ﬁbres that reﬂect centrally-mediated pain
McNamara et al., 2007). The late phase, on the other hand, cor-
esponds to the inﬂammatory-mediated nociceptive response, and
epresents the peripherally-acting nociception. This inﬂammatory-
nduced nociception is due to the action of various inﬂammation
ediators released due to damage to the cells resulting from forma-
in injection (Parada et al., 2001). It was reported that substance P
nd bradykinin act as mediators in the ﬁrst phase response, while
istamine, serotonin, prostaglandin and bradykinin are involved
n the nociceptive response of the second phase. It is well estab-
ished that, centrally acting drugs (i.e., opioids) can inhibit both
hases; however, peripherally acting drugs (i.e., NSAID) only inhibit
he second phase (Tjolsen et al., 1992; Mohd. Sani et al., 2012). In
he present study, MEMM  attenuated both phases of nociception
urther conﬁrming the extract’s centrally-acting effect.
In the early part of the discussion, MEMM  is suggested to prob-
bly possess a characteristic of strong opioid analgesics based on
he extract ability to inhibit the chemically- and thermally-induced
ocicpetive stimuli and to attenuate the nociceptive response in the
wo phases of formalin test. However, pre-treatment with nalox-
ne did not affect the antinociceptive activity of MEMM  against all
odels of nociception. This ﬁnding contradicted previous report
ade by Sulaiman et al. (2004), who demonstrated the involve-
ent of opioid system in the modulation of antinociceptive activity
f ethanol extract of M.  malabathricum (EEMM). This discrepancy
ould be due, particularly, to the different in route of administra-
ion of the respective extract. The effect of route of administration
an be seen in report by Matsumoto et al. (2004), wherein morphine
as reported to exert weak antinociceptive efﬁcacy when given via
he oral route in comparison to the subcutaneous route. In this case,
EMM was given intraperitoneally in comparison to MEMM,  which
as given orally. The bioactive compounds in MEMM  might have
ost or decreased in its opioid action due to metabolism processes
n the liver following the extract’s oral administration in compar-
son to EEMM,  which was  not metabolized by liver following its
ntraperitoneal administration and directly transfer to the site of
ction. The processes might have destroyed some of the antinoci-
eptive compounds, possibly those acting at the opioid receptors.
o further support the contradiction mentioned above, a report
y Rebolledo et al. (2012) could be used to explain the discrep-
ncy in opioid receptors role on the antinociception of MEMM  and
EMM.  According to Rebolledo et al. (2012), the polar compounds
ere easily digested than the non-polar compounds and this could
e used to explain the inability of naloxone to block the extract
ntinociception when administered orally, but not systemically.
Further tests were also conducted to examine the involvement
f MEMM  in the modulation of nociceptive transmission via the
anilloid receptors, glutamatergic system and NO/cGMP pathway.
o determine the role of vanilloid receptors in the modulation of
ntinociceptive activity of MEMM,  the capsaicin-induced paw lick-
ng test were carried out in rats. Capsaicin, the pungent substance
rom chilli peppers, has been repeatedly used in pain research
or its ability to induce both hyperalgesia and analgesia, depend-
ng on the concentration and route of application (Numazaki and
ominaga, 2004). Capsaicin has the ability to activate C- or A∂-ﬁbres
n afferent neurons through stimulation of TRPV1 receptors thus
llowing the inﬂux of Ca2+ and Na+ leading to neurogenic pain.
n addition, TRPV1 receptors are considered to be integrators of
oxious chemical and physical stimuli that can be activated by
apsaicin, heat and low pH (Numazaki and Tominaga, 2004). Pre-
ious studies have also shown that capsaicin induces the release
f neurokinins, neuropeptides, excitatory amino acids (glutamate
nd aspartate), nitric oxide (NO) and pro-inﬂammatory periph-
ral mediators, besides promoting the transmission of nociceptive
nformation to the spinal cord and the activation of vanilloid recep-
ors (Caterina and Julius, 2001). The vanilloid receptors also canmacognosia 26 (2016) 586–594
be sensitized or activated by several inﬂammatory mediators (i.e.,
bradykinin, nitric oxide and prostaglandin) and studies have shown
that activation of these receptors causes a sharp increase in inﬂam-
matory mediator levels (Cortright and Szallasi, 2004; Numazaki
and Tominaga, 2004). In the present study, MEMM  reversed the
capsaicin-induced nociception in a dose-dependent manner indi-
cating that the extract was  also effective in attenuating nociceptive
transmission modulated via the vanilloid receptors as well as inter-
fering with the release/action of those inﬂammatory mediators.
The latter ability might explain the extract potential to inhibit the
abdominal constriction test and the second phase of the formalin
test, which are related to the inﬂammatory-mediated nociception.
In an attempt to assess the ability of MEMM  to interfere with
the glutamate-mediated nociceptive transmission, the glutamate-
induced paw licking test was  performed. Glutamate, one of the
important excitatory amino acids, is most wide spread in the
central nervous system (CNS) (Neugebauer, 2002). It acts as a
major excitatory neurotransmitter where they participate in a
great number of physiological and pathological states. Glutamate
induces nociceptive transmission at the peripheral, spinal and
supra-spinal sites via different types of glutamate receptors (i.e.,
AMPA, Kainate and NMDA receptors) (Neugebauer, 2001a,b). Addi-
tionally, the nociceptive response induced by glutamate is greatly
mediated by both activation of N-methyl-d-aspartate (NMDA)
and -amino-3-hydroxyl-5-methyl-4-isoxazolepropionate (non-
NMDA) receptors, as well as releasing of NO or some NO-derived
substances (Beirith et al., 2002). The release of NO will trigger
the synthesis of pro-inﬂammatory mediators such as cytokines,
which help to enhance the inﬂammatory reaction (Beirith et al.,
1998, 2002). Moreover, there were reports that the activation of
glutamate receptors contribute to the maintenance of peripheral
nociceptive process associated with inﬂammation (as seen in the
late phase of formalin test) (Neugebauer, 2002), while the presence
of glutamate receptors antagonist inhibited the inﬂammatory (late
phase), but not neurogenic phase of the formalin test (Bhave et al.,
2001). In the present study, oral administration of MEMM  exerted
a dose-dependent inhibition of the glutamate-induced nocicep-
tive response. Therefore, it is strongly suggested that the MEMM
antinociceptive activity against the glutamate-induced nociception
occurs through the interaction of respective extract with any gluta-
mate receptors in the glutamatergic system or by interfering with
the NO production.
To investigate the role of NO/cGMP pathway in the modulation
of MEMM  antinociceptive activity, the extract were pre-challenged
against l-arginine (acts as a NO donor), l-NAME (acts as an inhibitor
of NO synthase) and MB  (acts as an inhibitor of cGMP pathway). NO,
a biological molecule found inside and between cells, is a major
player in physiological functions such as the impulse transmis-
sion in the central and peripheral nervous systems (Garthwaite
and Boulton, 1995). It has been reported that NO is involve in
the mechanism of nociception at the supraspinal and peripheral
sites by acting as a pro-nociceptive or an antinociceptive agent
depending on the doses presence (Ferreira et al., 1991; Machelska
et al., 1997). From the results obtained, only l-arginine signiﬁcantly
reversed MEMM’s  antinociception suggesting that the presence
of NO reduced but did not inhibit the extract’s antinociceptive
potential. Hence, it is plausible to suggest that MEMM  works via
the NO-mediated/cGMP-independent pathway. It has been well
acknowledged that NO exerts various biological roles that are medi-
ated in a cGMP-independent manner. For example, NO has been
shown to interact directly and indirectly with various inhibitory
neurotransmitters such as GABA, glycine, opioid, and muscarinic
receptor mechanisms (Ichinose et al., 1998; Cui et al., 2005).
Several classes of bioactive compounds have been detected in
MEMM,  namely ﬂavonoids, tannins, saponins, triterpenes. Recent
study using the HPLC analysis has also reported the presence
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f quercitrin in the extract (Kamisan et al., 2014). The ability
f quercitrin to inhibit the pro-inﬂammatory mediators, espe-
ially cytokines, engaged in pain modulation has been reported
Comalada et al., 2005; Gadotti et al., 2005), thus, suggested the
ompound to partly responsible for the observed antinociceptive
ctivity of MEMM.  In the present study, GCMS analysis was  per-
ormed on MEMM  and approximately 53% of the constituents
etected were fatty acid amide, namely 9-octadecenamide, hex-
decanamide and myristamide. The present of fatty acid amide
ight contribute to the observed antinociceptive activity of
EMM  based on previous reports that several fatty acid amides
emonstrated antinociceptive activity (Dray and Dickenson, 1991;
éciga-Campos et al., 2007; Barrière et al., 2013). Derivatives
f 9-octadecenamide (Dray and Dickenson, 1991) and hexade-
anamide (Déciga-Campos et al., 2007), in particular, have been
roven to exert antinociceptive activity and, hence, are believed
o contribute to MEMM’s  antinociceptive activity. Nevertheless,
urther studies are needed to reﬁne and validate these early
ndings.
onclusion
In conclusion, MEMM  exerted a non-opioid antinocicepitve
ctivity at the peripheral and central levels via mechanisms
nvolving modulation of the vanilloid receptors, glutamatergic sys-
em, and NO-mediated/cGMP-independent pathway. Moreover,
he antinociceptive activity of MEMM  might be attributed to
he presence of ﬂavonoid-based bioactive compounds, including
uercitrin. The ability to exert a non-opioid antinociceptive activ-
ty at the peripheral and central level suggests that the extract could
e a good candidate for the development of new analgesic drug that
s lack of dependence/tolerance effects seen with morphine.
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